Members of a key reimbursement policy panel on December 6 continued to push for the creation of separate generic price bands for both middle and lower bands under the current three price-band grouping rule as a way to address unreasonable…
Astellas’ HIF-PH Inhibitor, Trintellix, Venclexta, and Many More OK’ed for Listing on Nov. 19
To read the full story
Related Article
REGULATORY
- 6 Drugs Face Generic Entries, 2 Firms to Roll Out Symbicort Copies: December Listing
December 12, 2019
- Xolair Adds Pollen Allergy Use in Japan after 19-Day Delay
December 12, 2019
- Cosentyx, Lumicef Get Orphan Status for Add’l Indications
December 11, 2019
- “Third Price Revision” Eyed for Expansion of Comparator PMP Deduction Rule
December 11, 2019
- Metformin Manufacturers Ordered to Test for Potential Carcinogen Contamination
December 10, 2019
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…